Member Info for sadoldgit

My take on that Hbd is the CPF will have paid the patent servicing fees, unless of course it has been on licensed.

As you say a great deal of work was carried out by Sierra Oncology to which Michelle Garratt was an advisor.

The new licence info we have been given information on is basically a continuation of the old licence as similar milestone payments.

This does strike me as a little odd.

Maybe an ex director of SO involved? New company formed?

I will if can find time try and look at rcentlyl formed companies and approx market cap and number of shares issued. It does strike me as not too distant to the Acrivon deal for Prexasertib

100 million dollar fund raise was over subscribed so that had no problem with finance.

Prexasertib from memory was discontinued due to adverse effects mainly myocarditis of which no such events were attributed to SRA737 during the trials.

Also take into consideration that 737 was administered to clinical trial patients that had recieved previous therapies and realistically no other effective treatment available to them.

737 halted disease progression well. 737 effective at preventing new cancer growth until eventually resistance to CHK1 occurs whereby the Cancer then evades the p53 checkpoint and utilises a different pathway. Hence effectiveness very likely to have far greater efficacy when used in combo.

Much work was undertaken by Michelle Garrett and the University of Kent up to mid 2020.

Some news on licence development certainly would not go amiss.

Regards

Good posting as always from you PC1954.

Never a any reason to respond to you in a vitriolic way as a member suggested here that has contributed virtually nothing to this bb.

My line of thinking is that Sareum will have an option. Correct me if l am wrong but Sareum basically financed to end of 1a at the present.

Nothing can gain any value until a milestone us met.

Phase 1a opens the door via the compound being acceptable to proceed to the next level and hence removes a risk of failure.

Ideally we would run to end of phase 1b.

However, Sareum being in discussions with interested parties will have via informal discussions valuations at certain stages.

Hence successful phase 1b results great.

Previous post l have suggested that as from the end of phase 1a an onlicence may evolve.

Realistically the is the earliest point not just for a pharma to become involved due to data,provided but also as an alternative investment.

Until phase 1a data is realised then nothing of any substance can have a material effect on market cap and hence the SP.

I would like to think that Sareum are working on this and if they are then playing a very tight game.

I do not believe that sareum would release any info regarding due to the RF deal they are looking at alternative forms of finance. The market l believe would act very negatively to this.

Data is crucial and as they stated in 2022 AGM that is what the interested parties want.

The science side l have 100% confidence in their end product but their insight of ability to finance at or near an optimum time leaves vast room for improvement.

Regards

As much as said l will not be posting for a while until news on any front, l believe it us important to read and take note of the below link.

https://www.rbccm.com/en/gib/biopharma/episode/raising-capital-a-new-playbook-for-a-new-era-in-biotech

Regards

Shepardherdollar. I have been buying too!

I will co time to add and comfortably can add another 20k financially.

It is what it is caused by the k ock on effects of a senile corrupt old president in the US creating a war with Russia. The US have benefitted at the cost of severe financial problems in Europe.

Escalating energy prices. Caused by cutting off or to be more precise destruction of pipelines not destroyed by Russia. Inflation and difficulties arise.

As for Tim and Co raising funds at one time easy. That no longer the case.

How would Tim and Co be expected to predict this change in financial markets?

It is difficult for them. Remember when they took pay cuts to allow further development when funds were low.

Sareum have tried their damnest to overcome problems and we can take the MHRA debacle as one.

They are committed to achieving success with our compounds.

It galls me that some here who l used to regard as prominent Sareum investors seek blood from the board.

Yes the board could have raised money earlier on

And yes the investor could have sold at a high.

Who is at fault here.

I could have sold more at a high. But l can assure you one thing is that l have and will be buying at these levels.

I am sure the BoD are working on it. It will not be easy.

As l have said before the data from early stage trials are absolutely crucial.

Sareum will have an idea of what the compound is worth now with no data and also with positive data. Also of phase 1b data.

To get investors on board they need to know potential values of the compound on at least safety data and thus can be derived to a certain extent on informal discussions.

As we sit at the moment bugger all. Data required!

If you are positive then add if you not then sell.

No point in moaning!

I shall not be posting for a while. I have expressed the benefits which l believe very positive to what we have.

No point in posting anymore as immaterial until we get data results.

Regards to all faithful long term holders.

Value of company is based on initially the safety fata results of our compounds.

Preclinical was excellent with no MTD established and 30 times treatment dose was achieved with no difficulty.

How would you value the compound should we prove satisfactory safety data equal to or surpass Deucravacitinib?

Tyk2 Jak1 should prove far more effective in Tyk2 alone,

The addition of biomarker data will indicate areas that 1801 will prove to have most potential.

Put a value on 1801 with good data. How much will a player in this game pay?

Deucravacitinib an allosteric Tyk2 failed in UC so by definition is not as good as it was hyped up to be. All it did was to establish a satisfactory safety profile which of course is beneficial to us.

In Psoriasis l have 100% faith that our compound will outperform Deucravacitinib as has dual inhibition. It had been postulated years ago but again there were safety concerns of Jak1 2 and 3.

As we all know there is nothing as such as Jak1 only as all we have is selectivity over Jak2 and 3. That is all it can ever be. But selectivity can be improved. The compound is as strong as its weakest link. That denotes initially its safety profile.

Jak2 is deemed to have associated side effects.yet we have new compounds of Tyk2 znd Jak2 in development by a company which believe they can easily achieve better results than Deucravacitinib.

Tyk2 will interact with Jak2 so this may lessen the burden of Jak2 off target effects. I don't know. But then companies that go down this path have greater understanding than 5 years ago. Much greater understanding than me too!

I will put again. What value can you place on a compound that is equal to or not better performing Deucravacitinib?

Regards

There is no reason as to why 1801 can not go fron phase 1b to phase 3 study.

Phase l is toxicity/safety profile. Phase lb is small patient group phase very little different to phase 2 trial. Phase 2 looks at small numbers looking at efficacy in an indication, Phase 3 is larger patient numbers typically in the hundreds following satisfactory progress of phase 2 with no unsatisfactory results.

All importance safety data. If safety data is spot on with little to no toxicity at 300 mg per day and treatment profile delivers good efficacy at 100 mg per day in psoriasis then there would be no need for phase 2 in Psoriasis.

Just a scenario l am not saying this will happen just that l see it as a very real probability.

Regards

Good morning KoolKat15, no problem.

Yes indeed here is very frustrating.

Sareum have never experienced difficulty in obtaining decent from what l remember.

Delay caused by MHRA not help. War in Ukraine not help with corresponding rocket in price of energy.

Very heavy investment in military production. From memory around 2.5 trillion dollars spent on military equipment in 2022.

A vast proportion of this equipment is made by the US.

Military manufacturing companies have seen their SP triple on some cases.

Investors are attracted to thus as you will know as a steady gain with little to no risk is seen better than massive gain with moderate risk.

What we have has not changed with regards to a compound or compounds that have the potential to become commercially viable.

What has changed is peoples perception as an investor.

We are much further forward than 2021 when at a high. Nothing has changed with our compounds.

737 development has stopped and now looking like kick starting, of course if funding is readily available.

All AIM pharma suffered badly not by what they are researching and developing but by lack of suitable finance and investment.

It will return l believe as knock down severely overdone. As to when you most likely have a better idea than me and l don't think the 5 year period from 2021 is far out.

From.memory the options to the HNWI was around 2025/26.

The yanks are very content for a war to continue in Ukraine or indeed spread to Europe. They are more than happy to have NATO troops in Ukraine as long as they are not American. Effectively the US has created war with Russia using Ukranian people as cannon fodder.

Is it not better to concentrate on developments to save or improve people's lives as opposed to mass destruction?

Have a great weekend and l am very certain that on good data release we will indeed move upwards. At the very least on good data it will open up investment/finance opportunities far more tolerable than what we have now.

Regards

Nice to be informed l have got it wrong when in the past when we sat at sub 0.3 p in old money and was adding when l could and stating the price would be over a penny (pre dilution) over 2p over 3p or 4p and looking forward to the 10p party ( it never quite made it)

I believe the price dill rise significantly on good data results. I have added over 40 k shares in past few months that indicate my belief. Will continue to add without any undue stress.

I am not always right, that l will admit. Don't put me in the same light as that Workinginpharma either!

But koolkat surely even you should be able to string a sentence together that makes sense

'This share is not going nowhere fast'. If it is 'not going nowhere' then it must be going somewhere.

By all means if you are not happy here, and that is easy to deduce by the content of your posting then feel free to sell and move on.

I wish you all the best

Regards

Interesting if you look at the risk regarding phase levels to risk.

https://www.ourcrowd.com/learn/is-biotech-a-good-investment#:~:text=A%20Growing%20Industry&text=likely%20to%20increase.-,Research%20indicates%20that%20the%20industry%20is%20likely%20to%20grow%20at,13.96%25%20between%202023%20and%202030.&text=As%20with%20any%20rapidly%20growing,room%20for%20growth%20and%20investment.

That really is as l see it Cater19, irrespective of wether a poster is positive to this share or not.

Tim and Co have very little to go on at the moment to negotiate with . Data is of paramount importance.

The data is reliant on the compounds which are scientifically derived.

It is our first ever compound wholly owned by Sareum to enter clinical trial.

It is what it is until the wait for data has finished.

Regards to all.

RF finance has decimated the Sareum SP.

However, does this represent a true value as to what we have?

Market Cap of around 33 million.

Yes there is uncertainty and to this extent until safety data is released this uncertainty will remain.

Nothing of any benefit whether on going discussions informal offers or whatever can happen until this data has been evaluated and presented to an interested party.

737 developments wait to be seen and until any positive developments are released it will have little to no positive effect on SP.

It boils down to just how safe and in what indications SDC1801 most likely to prove fruitful.

Safety data on SDC 1801 will also have knock on effect to 1802.

I believe there will be very beneficial options once data is realised. Whether this arises as joint venture, on licence or even complete buyout of Sareum as surely at current Market Cap does not represent a true value of what we have.

1801 completing clinical safety trial, biomarker data albeit in low numbers but will give early Indications, knock on effect to 1802 which although progressing, l believe very slowly due to current funding.

I have added over past few months around 38k shares.

I will add further, certainly not for the faint hearted.

Regards and keep your chins up.

I hate just about sums it up Gunner68.

Data required re safety profile, minimum

Biomarker data up the price.

Psoriasis data if we still have 1801 after the above but considerably higher value following satisfactory results.

At this stage if a large pharma, will want 1801 in its entirety l would think and consideration in 1802.

Regards

It will ensure that a dosing schedule is safe to administer at 300mg per day. It does not place any limits as to higher dosing that may be required in different Indications.

A lot will depend on potency of compound.

The crucial stage of data results will soon become available and hence further waiting game, nothing we can do at the moment. We will have early data but l not think that sufficient to warrant RNS.

I presume that Sareum are still in discussions with interested parties. They will require comprehensive data to start the ball rolling.

Regards

Regards

However, l will add that as as a capsule formulation it may well be that it is not essential to take on an empty stomach. There are benefits of course to capsule formulation as not in a solid state and much quicker absorbed than by tablet.

Regards

Goodmorning Gumner68 , with regards to food phase trial l do not contemplate any requirement to continue to higher levels of dosing.

No need as basically looking at compound uptake not being compromised by food or certain foods that may have an effect.

Effectively it comes down to being is there a requirement to take the oral capsule on an empty stomach. Certain foods may slow or hinder uptake.

It may well be that the capsule may be administered on an empty stomach and 1 hr later you can have a meal.

It maybe that it is ok to take on a non empty stomach but my own personal opinion is this will not be the case. I may be wrong.

Regards.

Whoops forgot to add that 737 has a dosage therapy up to 800mg per day. Over 1000 mg per day up to 1300 mg toxicities started to become a problem

As l have said many times before l have never heard any news of problems of obtaining maximum tolerated dose of 737 at 30 times dosage with no adverse toxicities as has been the case with 1801.

1892 Sareum have to be careful whilst not wanting to rapidly progress 1802 due to burn up of cash availability for 1801 it will progrss albeit at a slower rate. Not necessarily a bad thing.

Regards and super weekend to all.

Data is of the upmost importance Gunner68. The data and nothing else will open the doors.

Are we safe to Use? Just how Safe? Faith in compounds.

Now if you remember the Sareum therapeutic data of treatment from 12.5mg per day upwards to 1000 mg per day.

737 had intended treatment range of up to 1000 mg per day. Over 1000 mg per day toxity approaching unacceptable ( not the correct term l will add). There was never any mention by Sareum in preclinical about 30 times treatment dosage being achieved with no undue toxicity with 737.

1801 had been used at 30 times dosaging regime with no toxicity concerns at all and were looking at 100 times, but as far as l know these levels were never attempted. Being able to supply enough of the compound was proving difficult at the time. A very similar problem with Aurora + FLT 4 being able to be supplied in sufficient capacities for clinical use and from whence a problem with solubility was encountered.

A problem for 1801 in thar there has never been a maximum tolerated dose established which is nearly a requirement to start clinical trials. 30 x the maximum dose can be taken but is not guaranteed. The Aussies chose a similar factor based on other similar jaki inhibitors and restricted this to approximate safety dosages to this regime.

With regards to a piddly 300 mg per day l am of the firm belief that all will bode very well on escalating safety dosing.

So much effort and attention to detail gone into

To our TYk2 Jak 1 compounds made of the patented protected molecules used to formulate these compounds l have the upmost faith.

Regards

Just how during how many here realised that Michelle Garrett was working as an advisor for Sierra Oncology.

Many of the recent reports with 737 is basically info nigh identical to research data carried out by M Garrett and Co. This looked at Wee1 and several other combinations with all the pluses and minuses.

Work was still being carried out up until mid 2020.

Good evening PC1954, it I nice to be back home, yes l am at Sizewell on the B site at the moment.

Looking forward to a beer or two if and when we take off.

Regards.

For the point of view of investors potnak it boils down to how much faith we have in the Compound.

I am 100% in faith with Compound

Bringing an investor on board with no understanding of the history is extremely difficult in current financial climate.

Phase1 data being good we will get an update on the most important aspect is how interested perceive and interpret this data with corresponding informal discussions.

Tyk2 compounds are a hot topic. Tyk2 with corresponding addition of Jaki inhibitors even hotter , but safety profile here is of paramount importance

Your 2 billion valuation at later stage is achievable on good results.

As I have said before we do not k ow what is going on in the background.

Deals are not made overnight. It takes years sometimes to reign in a reputable company to invest or whatever means to come to mutually agreeable financial arrangement.

Tablet formulations while less expensive to produce run the risk of a percentage of the tablet running through the entire gastrointestinal tract undigested and the administration and up take to the body is compromised.

Pit a value on this at end of phase 1 a trial. Any upfront significant payment or partnership contribution will remove the need for the parasitic life blood sucking effects of the likes of RF. A smaller up front payment and financial deal may be the downside, the upside of course would be the removal of the vital but poor finance package with RF.

Easier said than done, bit we need to produce satisfactory safety data from dose escalation to get the ball running.

Regards to all.